The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia

To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L 2 regimens was implemented in the year 1993. The patients were classified as being st...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2008
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22419
Acceso en línea:
https://doi.org/10.1097/MPH.0b013e31817e4a7d
https://repository.urosario.edu.co/handle/10336/22419
Palabra clave:
Antineoplastic agent
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Folinate calcium
Mercaptopurine
Methotrexate
Prednisone
Acute lymphoblastic leukemia
Adolescent
Article
Cancer chemotherapy
Cancer mortality
Cancer radiotherapy
Cancer regression
Cancer relapse
Cancer risk
Cancer survival
Central nervous system
Child
Colombia
Controlled study
Cytogenetics
Drug dose reduction
Drug megadose
Female
Human
Infant
Major clinical study
Male
Multiple cycle treatment
Preschool child
Priority journal
School child
Treatment outcome
Treatment response
Adolescent
Antineoplastic combined chemotherapy protocols
Central nervous system neoplasms
Child
Cohort studies
Colombia
Cranial irradiation
Cytogenetic analysis
Humans
Infant
Precursor cell lymphoblastic leukemia-lymphoma
Prednisone
Recurrence
Remission induction
Risk
Survival rate
Cns-leukemia
Developing country
Intensive chemotherapy
Pediatric all
preschool
Child
Rights
License
Abierto (Texto Completo)
Description
Summary:To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L 2 regimens was implemented in the year 1993. The patients were classified as being standard risk (SR) or high risk (HR) according to clinical criteria, to which cytogenetic information and day-8 prednisone response were also added. A 123-patient cohort entered the study, 18 of them being considered SR and 105 HR. There was a 94% 10 years' event-free-survival rate for the SR group and 36% for the HR group. Decreased induction death rate (7% vs. 14%), increased complete remission (CR) rate (81% vs. 75%), and continuous CR (45% vs. 33%) were found in comparison with the previous study. A significant improvement was achieved in relapse rate, 44% to 28% (P=0.029), mainly due to reduced central nervous system relapse rate from 16% to 6% (P=0.037), whereas the number of patients receiving cranial radiation was reduced to 55%. A major problem concerned the increased CR mortality rate, 5% to 14% (P=0.06). Improved supportive care therapy and socioeconomic conditions will hopefully reduce the CR mortality rate in the future. © 2008 by Lippincott Williams and amp; Wilkins.